Was Rova-T Worth The High Price To AbbVie?
Executive Summary
The big pharma presented early-stage data for its antibody drug conjugate at the American Society of Clinical Oncology (ASCO) in Chicago that showed promise for the drug in a small subset of patients with small cell lung cancer, but had disappointing results for the overall population.
You may also be interested in...
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
AbbVie boosted its revenue guidance, increasing its longer-term Humira forecast from $18bn in 2020 to $21bn, raising the bar for drugs that will make up for revenue lost when biosimilar competition arrives in five years.
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
AbbVie boosted its revenue guidance, increasing its longer-term Humira forecast from $18bn in 2020 to $21bn, raising the bar for drugs that will make up for revenue lost when biosimilar competition arrives in five years.
Stockwatch: ASCO Controversies
Despite the early sell-off in life science stocks during last week’s American Society for Clinical Oncology (ASCO) conference, there were some very positive new developments for cancer patients. The only problem now is the question of who will pay for combination treatment regimens.